Compare Public Storage (PSA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Storage vs Travere Therapeutics Inc. Common Stock — how do they compare? Public Storage trades at $290.77 (market cap $53.89B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Public Storage is far larger — about 11× Travere Therapeutics Inc. Common Stock's market cap, and Public Storage pays a 4.16% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Public Storage for 130 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PSA | TVTX | |
|---|---|---|
Market Cap | $53.89B | $4.88B |
Volume | 947,047 | 1,668,577 |
Sector | Real Estate | Health |
52-Week High | $330.47 | $67.52 |
52-Week Low | $258.44 | $26.79 |
Typical Hold Time | 130 Days | 0 Days |
Enterprise Value | $68.16B | $5.01B |
Dividend Yield | 4.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Storage (PSA) trades at $288.76, showing minimal daily movement (-0.04%) with neutral technical indicators. The REIT maintains strong fundamentals including a 41.8% net income margin and consistent earnings beats, though valuation metrics appear elevated with a P/E of 27.52. Recent developments include the completion of the Public Storage Canada acquisition and a $400 million Canadian debt offering, positioning for strategic growth.
PSA presents a mixed outlook with analyst consensus pointing to 14% upside to the $328.33 price target, though the majority (64%) recommend Hold. Key risks include REIT sector sensitivity to interest rates and competitive pressures, while the 4.05% dividend yield provides income stability. The stock's premium valuation requires sustained operational execution to justify further gains.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
